Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 25, 2026, 11:39 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 880 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Immunological Tolerance Clear all
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Piloting a School-Based Distress Tolerance Skills Program for Adolescents

NCT06638853
View directory record Official record
Conditions
Distress, Emotional, Internalizing Mental Health Symptoms
Interventions
Distress Tolerance Skills Training
Behavioral
Lead sponsor
Oregon Health and Science University
Other
Eligibility
11 Years to 14 Years
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Beaverton, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 23, 2025 · Synced Jun 25, 2026, 11:39 PM EDT
Completed Not applicable Interventional

A Study of Nevirapine Used Alone or in Combination With AZT in HIV-1-Infected Children

NCT00001111
View directory record Official record
Conditions
HIV Infections
Interventions
Nevirapine, Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Day to 17 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
7
States / cities
Los Angeles, California • Farmington, Connecticut • Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2011 · Synced Jun 25, 2026, 11:39 PM EDT
Completed Phase 2 Interventional Results available

Combination Drug Therapy Followed by Single Drug Steroid Free Therapy to Prevent Organ Rejection in Kidney Transplantation

NCT00076570
View directory record Official record
Conditions
Kidney Transplantation
Interventions
Sirolimus, Tacrolimus
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
Not listed
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 15, 2013 · Synced Jun 25, 2026, 11:39 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis

NCT00104299
View directory record Official record
Conditions
Vasculitis, Wegener's Granulomatosis, Microscopic Polyangiitis
Interventions
Rituximab plus cyclophosphamide placebo (rituximab group), Cyclophosphamide plus rituximab placebo (control group), Azathioprine, Methylprednisolone (or other glucocorticoid), Prednisone
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
15 Years and older
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
7
States / cities
Birmingham, Alabama • Baltimore, Maryland • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2017 · Synced Jun 25, 2026, 11:39 PM EDT
Recruiting Phase 1Phase 2 Interventional

Immune Tolerance Induction After Liver Transplantation

NCT07269041
View directory record Official record
Conditions
Liver Transplantation, Immune Tolerance, Immune Tolerance/Drug Effects, Graft Survival, Hematopoietic Stem Cell, Chimerism, Immunosuppression After Liver Transplantation, Immunosuppression Disorders, End Stage Liver Disease
Interventions
Donor Hematopoietic Stem and Progenitor Cell Infusion
Biological
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Jun 25, 2026, 11:39 PM EDT
Completed Not applicable Interventional

Self-Administered 2-Hour Oral Glucose Tolerance Test

NCT06099509
View directory record Official record
Conditions
Gestational Diabetes, Postpartum Disorder, Gestational Diabetes Mellitus in Pregnancy
Interventions
Self-administered oral glucose tolerance test
Other
Lead sponsor
Prisma Health-Upstate
Other
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 1, 2025 · Synced Jun 25, 2026, 11:39 PM EDT
Completed Phase 1 Interventional

Safety, Tolerance, Efficacy and Pharmacokinetics of Multiple Doses of sCD4-PE40 in the Treatment of HIV-Infected Individuals

NCT00002087
View directory record Official record
Conditions
HIV Infections
Interventions
Alvircept sudotox
Drug
Lead sponsor
Pharmacia and Upjohn
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jun 25, 2026, 11:39 PM EDT
Completed No phase listed Observational

Evaluation of Low Source of Signal in SCOUT DS

NCT01339637
View directory record Official record
Conditions
Metabolic Syndrome, Impaired Glucose Tolerance, Gestational Diabetes
Interventions
Not listed
Lead sponsor
VeraLight, Inc.
Industry
Eligibility
18 Years and older
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
5
States / cities
Birmingham, Alabama • Atlanta, Georgia • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2012 · Synced Jun 25, 2026, 11:39 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Pregnyl as Adjunct Therapy for High-Risk or Refractory Acute GVHD

NCT02525029
View directory record Official record
Conditions
Graft vs Host Disease
Interventions
Pregnyl®
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 76 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 13, 2023 · Synced Jun 25, 2026, 11:39 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Vitamin D, Insulin Sensitivity, and Vascular Associations in Adolescents

NCT01041365
View directory record Official record
Conditions
Insulin Sensitivity, Flow-mediated Dilation, Arterial Stiffness
Interventions
Not listed
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
14 Years to 18 Years · Female only
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 13, 2014 · Synced Jun 25, 2026, 11:39 PM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Effect of Omecamtiv Mecarbil on Exercise Capacity in Subjects With Heart Failure

NCT03759392
View directory record Official record
Conditions
Heart Failure With Reduced Ejection Fraction
Interventions
Omecamtiv Mecarbil, Placebo
Drug
Lead sponsor
Cytokinetics
Industry
Eligibility
18 Years to 85 Years
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
36
States / cities
Anchorage, Alaska • Little Rock, Arkansas • Torrance, California + 31 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2023 · Synced Jun 25, 2026, 11:39 PM EDT
Terminated Phase 3 Interventional Results available

The Hemophilia Inhibitor Eradication Trial

NCT04303572
View directory record Official record
Conditions
Hemophilia A With Inhibitor
Interventions
Eloctate ITI, Emicizumab
Drug
Lead sponsor
Margaret Ragni
Other
Eligibility
Male only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 20, 2023 · Synced Jun 25, 2026, 11:39 PM EDT
Completed Not applicable Interventional

The Safety and Effectiveness of Isoprinosine in Patients With Weakened Immune Systems and Lymph Node Disease

NCT00002296
View directory record Official record
Conditions
Lymphatic Disease, HIV Infections
Interventions
Inosine pranobex
Drug
Lead sponsor
Newport Pharmaceuticals International
Industry
Eligibility
18 Years to 50 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Laguna Hills, California
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jun 25, 2026, 11:39 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study to Determine and Compare the Tolerance and Irritation Potential of Topical Acne Medications

NCT00964366
View directory record Official record
Conditions
Acne Vulgaris
Interventions
clindamycin and benzoyl peroxide, Dapsone gel
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
18 Years to 45 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Broomall, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Jun 25, 2026, 11:39 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Immune Tolerance and Alloreactivity in Liver Transplant Recipients on Different Monotherapy Immunosuppressive Agents

NCT01678937
View directory record Official record
Conditions
Liver Transplant Rejection, Immunosuppression
Interventions
Blood Draw - Rapamycin, Blood Draw from Control Subjects, Blood Draw - CyA, Blood Draw - Tacrolimus, Blood Draw - MMF
Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 14, 2015 · Synced Jun 25, 2026, 11:39 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Tolerance of Infants Fed a Hydrolysate Formula

NCT03628183
View directory record Official record
Conditions
Gastrointestinal Tolerance
Interventions
Hydrolysate Infant Formula 1, Hydrolysate Infant Formula 2
Other
Lead sponsor
Abbott Nutrition
Industry
Eligibility
Up to 14 Days
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
5
States / cities
Tucson, Arizona • Owensboro, Kentucky • Cleveland, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2018 · Synced Jun 25, 2026, 11:39 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Efficacy and Safety of 12-weeks Supplementation of Eubacterium Hallii on Insulin Sensitivity and Glycaemic Control

NCT04529473
View directory record Official record
Conditions
Pre Diabetes, Impaired Glucose Tolerance, Insulin Sensitivity, Insulin Resistance, Glucose Metabolism Disorders, Metabolic Syndrome
Interventions
Eubacterium hallii, Placebo
Dietary Supplement · Other
Lead sponsor
Atlantia Food Clinical Trials
Industry
Eligibility
21 Years to 69 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 14, 2022 · Synced Jun 25, 2026, 11:39 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Growth of Healthy Term Infants Fed Formula Containing DHA-B

NCT02144402
View directory record Official record
Conditions
Growth, Tolerance, Infant Development
Interventions
infant formula with DHASCO, infant formula with DHASCO-B
Other
Lead sponsor
dsm-firmenich Switzerland AG
Industry
Eligibility
1 Day to 14 Days
Enrollment
159 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
10
States / cities
Dothan, Alabama • Jonesboro, Arkansas • Norwich, Connecticut + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2015 · Synced Jun 25, 2026, 11:39 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of TCD601 in the Induction of Tolerance in Renal Transplantation (PERSPECTIVE)

NCT04803058
View directory record Official record
Conditions
Kidney Transplantation
Interventions
TCD601
Biological
Lead sponsor
ITB-Med LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
2
States / cities
Boston, Massachusetts • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Jun 25, 2026, 11:39 PM EDT
Not listed Not applicable Interventional

Effects on Glycemic Control of WBF-0031 in Subjects With Abnormal Glucose Tolerance

NCT04490460
View directory record Official record
Conditions
Abnormal Glucose Tolerance
Interventions
WBF-0031
Dietary Supplement
Lead sponsor
Eden Miller
Industry
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Bend, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 28, 2020 · Synced Jun 25, 2026, 11:39 PM EDT
Not listed Phase 4 Interventional

Rosiglitazone Therapy In The Prevention Of Coronary Artery Disease In Patients With Impaired Glucose Tolerance

NCT00733174
View directory record Official record
Conditions
Impaired Glucose Tolerance
Interventions
Rosiglitazone, Placebo
Drug
Lead sponsor
Denver Research Institute
Other
Eligibility
25 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 11, 2008 · Synced Jun 25, 2026, 11:39 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Tolerance and Pharmacokinetic Study of Trodusquemine in Healthy Volunteers

NCT00509132
View directory record Official record
Conditions
Obesity
Interventions
trodusquemine
Drug
Lead sponsor
Genaera Corporation
Industry
Eligibility
18 Years to 55 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 8, 2008 · Synced Jun 25, 2026, 11:39 PM EDT
Completed Phase 2 Interventional Results available

Metabolic Effects of Paricalcitol

NCT01003275
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Paricalcitol, Placebo
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 27, 2014 · Synced Jun 25, 2026, 11:39 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Safe, Effective, and More Tolerable 16 Tablets Colon Prep

NCT00817934
View directory record Official record
Conditions
Colon Cancer
Interventions
AB PREP
Drug
Lead sponsor
Long Neck Medical Enterprises
Other
Eligibility
12 Years to 75 Years
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Millsboro, Delaware
Source: ClinicalTrials.gov public record
Updated Jan 6, 2009 · Synced Jun 25, 2026, 11:39 PM EDT